The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Pick #1 is a biotech by the name of Aldeyra Therapeutics (ALDX). The reason why i want to go over this biotech ...
BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater ...
The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #4 is a biotech by the name of Cardiff Oncology (CRDF). The reason why I wanted to go over this ...
Biotech is shifting to hub-and-spoke models to share infrastructure, reduce single-asset risk, and build repeatable engines ...
Biotechnology startups are creating tiny models of human organs in an effort to speed the search for novel drugs. By devising more realistic models of human and disease biology, these startups aim to ...
The hallmark of the new economy is innovation. Pressure to incentivize the economy to facilitate innovation has been a key driver of intellectual property (IP) law for generations. For years, there ...
INDIANAPOLIS, Sept. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results